Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021
July 22, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2021 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, July 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
June 03, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
- Principal Repayments Delayed At Least Until January 1, 2022 - Repayment Delay and Recent ATM Activity Extends Cash Runway Substantially Through the First Quarter of 2022 DUBLIN, Ireland and...
Nabriva Announces Changes to its Board of Directors
June 02, 2021 18:02 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, June 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
May 25, 2021 17:00 ET
|
Nabriva Therapeutics US, Inc
Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure...
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 21, 2021 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 06, 2021 16:01 ET
|
Nabriva Therapeutics US, Inc
-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- -Commenced exclusive...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2021 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, May 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021
April 29, 2021 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...